Artwork

Content provided by Women in Ophthalmology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Women in Ophthalmology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

S01E01 Rituximab for Non-infectious Uveitis and Scleritis

11:07
 
Share
 

Manage episode 308189743 series 3011762
Content provided by Women in Ophthalmology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Women in Ophthalmology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Is Rituximab a Wonder-drug?

Dr Diana Conrad, Director of the Uveitis Service at the Royal Women’s and Children’s Hospital (the only speciality uveitis service in Queensland) explores a review paper on the use of rituximab for the treatment of non-infectious uveitis and scleritis. Dr Conrad notes an impressive response rate to rituximab for patients where first and second-line treatments have failed. Given the success of rituximab, and the biosimilars entering the market, Dr Conrad includes some important messages for ophthalmologists using the drug.
View article here

  continue reading

20 episodes

Artwork
iconShare
 
Manage episode 308189743 series 3011762
Content provided by Women in Ophthalmology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Women in Ophthalmology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Is Rituximab a Wonder-drug?

Dr Diana Conrad, Director of the Uveitis Service at the Royal Women’s and Children’s Hospital (the only speciality uveitis service in Queensland) explores a review paper on the use of rituximab for the treatment of non-infectious uveitis and scleritis. Dr Conrad notes an impressive response rate to rituximab for patients where first and second-line treatments have failed. Given the success of rituximab, and the biosimilars entering the market, Dr Conrad includes some important messages for ophthalmologists using the drug.
View article here

  continue reading

20 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide